ABT · Abbott GP
last $101.67+0.59%volume $10.95Mmarket cap n/afeed alpacaas of 2026-09-25 15:30
one year · daily closes52-week high $134.5852-week low $82.5551m -13.0%3m +8.4%1y -24.5%
FA · financials · ABBOTT LABORATORIES from the company's own filingsEDGAR ↗
| quarter ending | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| revenue | $11.16B | $11.46B | $11.37B | $11.14B | $10.36B | $10.97B | $10.63B | $10.38B |
| net income | $1.08B | $1.78B | $1.64B | $1.78B | $1.32B | $9.23B | $1.65B | $1.30B |
| EPS (diluted) | 0.61 | 1.02 | 0.94 | 1.01 | 0.76 | 5.26 | 0.94 | 0.74 |
| operating cash flow | $1.31B | $3.31B | $2.79B | $2.05B | $1.42B | $2.87B | $2.71B | $1.96B |
total assets $110.43B (2026-03-31)cash $6.80B (2026-03-31)long term debt $29.64B (2026-03-31)equity $52.06B (2026-03-31)shares outstanding 1,741,812,429 (2026-03-31)
quarterly figures as filed (10-Q / 10-K); where a company reports year-to-date, the quarter is the difference. No estimates.
news · ABTmore →
no matching headlines in the last hours